{{Rsnum
|rsid=7712023
|Gene=HMMR
|Chromosome=5
|position=163462952
|Orientation=plus
|GMAF=0.3485
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=HMMR
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 20.0 | 56.9 | 23.1
| HCB | 64.4 | 31.1 | 4.4
| JPT | 66.7 | 33.3 | 0.0
| YRI | 56.5 | 40.3 | 3.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 64.4 | 31.1 | 4.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}[http://cancergenetics.wordpress.com/2007/10/13/exciting-discoveries-of-2007-breast-cancer/ cancergenetics] The risk of [[breast cancer]] was 23% higher in women who had one copy of genetic variant (the A-C-A haplotype: [[rs7712023]]-[[rs299290]]-[[rs10515860]]), and 46% higher in women with two copies. In addition, those women were diagnosed an average of 12 months younger than women from the control group, suggesting that [[HMMR]] is linked to early-onset breast cancer.

However, a more recent, larger European case-control study found no association between [[rs7712023]] and risk of breast cancer.{{PMID|19065580}}

{{PMID|19064580}} [[breast cancer]]
*[[rs10515860]] [odds ratio (OR; AA/GG), 0.85; 95% confidence interval (CI), 0.65-1.12; P(trend) = 0.9], 
*[[rs299290]] [OR (CC/TT), 1.00; 95% CI, 0.87-1.15; P(trend) = 0.7], 
*[[rs3756648]] ([[rs7712023]]) [OR (TT/CC), 0.93; 95% CI, 0.84-1.02; P(trend) = 0.1], 
*[[rs299284]] [OR (TT/CC), 1.01; 95% CI, 0.76-1.35; P(trend) = 0.5], and 
*[[rs13183712]] [OR (TT/GG), 1.04; 95% CI, 0.88-1.23; P(trend) = 0.6].

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}